Compare SRCE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRCE | MESO |
|---|---|---|
| Founded | 1863 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1995 | N/A |
| Metric | SRCE | MESO |
|---|---|---|
| Price | $76.25 | $13.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $74.50 | N/A |
| AVG Volume (30 Days) | 99.5K | ★ 126.0K |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 19.59 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.29 | $629.74 |
| Revenue Next Year | $3.16 | $30.65 |
| P/E Ratio | $47.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.89 | $9.88 |
| 52 Week High | $79.08 | $21.50 |
| Indicator | SRCE | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 43.50 |
| Support Level | $71.36 | $13.71 |
| Resistance Level | N/A | $16.11 |
| Average True Range (ATR) | 1.45 | 0.48 |
| MACD | 0.18 | -0.05 |
| Stochastic Oscillator | 55.42 | 14.93 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.